Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
FENC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.21
vs -0.19
Q3.23
N/A
-0.07
vs -0.31
Q4.23
N/A
-0.10
vs -0.26
Q1.24
+304%
0.47
vs -0.23
Q2.24
N/A
-0.20
vs -0.21
Q3.24
N/A
-0.21
vs -0.07
Q4.24
N/A
-0.06
vs -0.10
Q1.25
N/A
-0.04
vs 0.47
Q2.25
N/A
-0.04
vs -0.20
Q3.25
+149%
0.1
vs -0.21
Sales Growth
YoY
Current
Estimates
Q2.23
NA
3.3M vs NA
Q3.23
NA
6.5M vs NA
Q4.23
+534%
9.7M vs 1.5M
Q1.24
+1413%
25.4M vs 1.7M
Q2.24
+118%
7.3M vs 3.3M
Q3.24
+7%
7M vs 6.5M
Q4.24
-19%
7.9M vs 9.7M
Q1.25
-66%
8.8M vs 25.4M
Q2.25
+33%
9.6M vs 7.3M
Q3.25
+93%
13.5M vs 7M
Return on Equity
QoQ
Q2.23
+56%
0.56
vs 0.82
Q3.23
+18%
0.18
vs 0.56
Q4.23
+23%
0.23
vs 0.18
Q1.24
+426%
4.26
vs 0.23
Q2.24
+409%
4.09
vs 4.26
Q3.24
+111%
1.11
vs 4.09
Q4.24
+29%
0.29
vs 1.11
Q1.25
-47%
-0.47
vs 0.29
Institutionnal Ownership
QoQ
Q2.23
60
60
vs 58
3%
Q3.23
59
59
vs 60
-2%
Q4.23
58
58
vs 59
-2%
Q1.24
67
67
vs 58
16%
Q2.24
62
62
vs 67
-7%
Q3.24
62
62
vs 62
NA
Q4.24
64
64
vs 62
3%
Q1.25
68
68
vs 64
6%
zacks.com
8 hours ago
seekingalpha.com
12 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Forecast
736%2026-Revenue
2219%2026-EPS
-3929%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Cantor Fitzgerald
upgradePrevious: Not converted
2022-11-22
Now: Overweight
Oppenheimer
initialisePrevious: Not converted
2022-09-07
Now: Outperform
Morgan Stanley
initialisePrevious: Not converted
2022-09-07
Now: Equal-Weight
Jefferies
initialisePrevious: Not converted
2022-09-07
Now: Buy
Quote Panel
Key Metrics
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.45 ( -5.51%)
After-hours 8.71$0.99 (12.89%)
Relative Strenght
85
Volume Buzz
15%
Earning Acce
Yes
Dist 52w H.
11%Relative Strength
FENC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|